GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (NAS:RVNC) » Definitions » Asset Turnover

Revance Therapeutics (Revance Therapeutics) Asset Turnover : 0.14 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Revance Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Revance Therapeutics's Revenue for the three months ended in Dec. 2023 was $69.8 Mil. Revance Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $505.5 Mil. Therefore, Revance Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.14.

Asset Turnover is linked to ROE % through Du Pont Formula. Revance Therapeutics's annualized ROE % for the quarter that ended in Dec. 2023 was 172.84%. It is also linked to ROA % through Du Pont Formula. Revance Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -44.08%.


Revance Therapeutics Asset Turnover Historical Data

The historical data trend for Revance Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revance Therapeutics Asset Turnover Chart

Revance Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.03 0.12 0.24 0.44

Revance Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.09 0.10 0.10 0.14

Competitive Comparison of Revance Therapeutics's Asset Turnover

For the Biotechnology subindustry, Revance Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revance Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revance Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Revance Therapeutics's Asset Turnover falls into.



Revance Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Revance Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=234.04/( (581.9+478.454)/ 2 )
=234.04/530.177
=0.44

Revance Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=69.799/( (532.487+478.454)/ 2 )
=69.799/505.4705
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Revance Therapeutics  (NAS:RVNC) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Revance Therapeutics's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-222.796/-128.9025
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-222.796 / 279.196)*(279.196 / 505.4705)*(505.4705/ -128.9025)
=Net Margin %*Asset Turnover*Equity Multiplier
=-79.8 %*0.5523*-3.9213
=ROA %*Equity Multiplier
=-44.08 %*-3.9213
=172.84 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Revance Therapeutics's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-222.796/505.4705
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-222.796 / 279.196)*(279.196 / 505.4705)
=Net Margin %*Asset Turnover
=-79.8 %*0.5523
=-44.08 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Revance Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Revance Therapeutics (Revance Therapeutics) Business Description

Traded in Other Exchanges
Address
1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Executives
Dwight Moxie officer: SVP, GC & Secretary 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Mark J Foley director ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Tobin Schilke officer: Chief Financial Officer 7000 SHORELINE COURT, #371, SOUTH SAN FRANCISCO CA 94080
Carey Oconnor Kolaja director C/O REVANCE THERAPEUTICS, INC, 1222 DEMONBREUN STREET, SUITE 1001, NASHVILLE TN 37203
Dustin S Sjuts officer: President 7555 GATEWAY BLVD, NEWARK CA 94560
Vlad Coric director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Aubrey Rankin director C/O REVANCE THERAPEUTICS, INC, 7555 GATEWAY BLVD, NEWARK CA 94560
Angus C. Russell director C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Olivia C Ware director 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Chris Nolet director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Jill Beraud director C/O LEVI STRAUSS & CO., 1155 BATTERY STREET, SAN FRANCISCO CA 94111
L Daniel Browne director, officer: CEO and President 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Cyril Allouche officer: Principal Financial Officer 7555 GATEWAY BLVD., NEWARK CA 94560
Lauren P Silvernail officer: CFO, Seretary & EVP Corp Dev. 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Caryn Gordon Mcdowell officer: SVP, GC & Secretary 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080